Leicester based healthcare company, Sprit Healthcare, has acquired the medical wearables and technology company Aseptika in the aim to expand its offering towards patients and healthcare professionals.
Spirit/Aseptika
The company will be utilising Aseptika’s Active8rlives range of self-monitoring solutions which people can use to improve their fitness levels through a range of health applications.
The technology will accompany Spirit’s own products such as its cloud-based service CliniTouch Vie. The service aims to help patients will respiratory diseases, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis. The service helps patients keep on track of their healthcare requirements as they change over time.
Spirit’s CEO Chris Barker said: “At Spirit, we believe that we can offer patients greater control over their own health by rethinking the way that care is delivered and Aseptika shares this vision. The Aseptika team has exceptional experience developing pioneering technology and we’re looking to grow this capability at their Cambridgeshire hub. With these skills, Spirit will be able to accelerate its programme of innovation. We’re innovating and growing fast so we can empower more patients across the UK. This significant acquisition is the second that we’ve made and we’re certainly on the hunt for more acquisition opportunities in the near future.”
Aseptika founder Kevin Auton commented: “We are delighted to be joining the highly successful Spirit group of companies in delivering the new technologies, solutions and services needed to support the growing healthcare needs of the UK. Spirit exemplifies the drive and innovation of the SME sector in delivering the technologies and services our NHS will need in the coming months and years as it accelerates towards digital delivery of healthcare to make its finite resources go further.
The companies have been supported through the Small Business Research Initiative for Healthcare (SBRI Healthcare). The companies are now collaborating to work on mobile technology to help improve management of type 1 diabetes. The project is based in Scotland as part of an SBRI competition.